Goldman Sachs Discloses 5.0% Stake in BioLife Solutions (BLFS)
Ticker: GSCE · Form: SC 13G · Filed: Feb 2, 2024 · CIK: 886982
| Field | Detail |
|---|---|
| Company | Goldman Sachs Group INC (GSCE) |
| Form Type | SC 13G |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, SC-13G, investment, equity-stake
TL;DR
**Goldman Sachs just revealed a 5% stake in BioLife Solutions, signaling institutional confidence.**
AI Summary
Goldman Sachs Group Inc. reported on February 2, 2024, that as of December 29, 2023, it holds a significant stake in BioLife Solutions Inc. (BLFS). This filing indicates that Goldman Sachs now owns 5.0% of BioLife Solutions' Common Stock, par value $0.001 per share. This matters to investors because a major financial institution like Goldman Sachs taking a substantial position can signal confidence in the company's future prospects, potentially influencing other investors and the stock price.
Why It Matters
A large institutional investment by Goldman Sachs could be seen as a vote of confidence in BioLife Solutions, potentially attracting more investor interest and positively impacting its stock valuation.
Risk Assessment
Risk Level: low — This filing indicates a significant institutional investment, which is generally viewed as a positive signal and reduces perceived risk.
Analyst Insight
Smart investors should research BioLife Solutions' fundamentals and consider if Goldman Sachs' investment aligns with their own investment thesis, potentially viewing this as a positive signal for the stock.
Key Numbers
- 5.0% — Ownership Stake (Percentage of BioLife Solutions Common Stock owned by Goldman Sachs.)
- December 29, 2023 — Event Date (The date that triggered the requirement for Goldman Sachs to file this statement.)
- 09062W204 — CUSIP Number (Unique identifier for BioLife Solutions' Common Stock.)
Key Players & Entities
- Goldman Sachs Group Inc. (company) — filer, reporting a significant ownership stake
- BioLife Solutions Inc. (company) — subject company in which Goldman Sachs holds shares
- 5.0% (dollar_amount) — percentage of BioLife Solutions' common stock owned by Goldman Sachs
- December 29, 2023 (person) — date of event requiring the filing
- $0.001 (dollar_amount) — par value per share of BioLife Solutions Common Stock
Forward-Looking Statements
- BioLife Solutions' stock price will see increased trading volume due to the institutional interest shown by Goldman Sachs. (BioLife Solutions Inc.) — medium confidence, target: Within 1 month
- Other institutional investors may initiate or increase their positions in BioLife Solutions, following Goldman Sachs' lead. (BioLife Solutions Inc.) — medium confidence, target: Within 3 months
FAQ
What is the specific percentage of BioLife Solutions, Inc. common stock that Goldman Sachs Group Inc. reported owning?
Goldman Sachs Group Inc. reported owning 5.0% of BioLife Solutions, Inc.'s Common Stock, par value $0.001 per share, as stated in the filing.
What was the 'Date of Event Which Requires Filing of this Statement' for this SC 13G?
The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023, as specified in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the filing.
What is the CUSIP Number for the class of securities reported in this filing?
The CUSIP Number for the Common Stock, par value $0.001 per share, of BioLife Solutions, Inc. is 09062W204, according to the filing.
What is the business address of the subject company, BioLife Solutions Inc.?
The business address for BioLife Solutions Inc. is 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021, as listed in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 2, 2024 by December 29, 2023 regarding GOLDMAN SACHS GROUP INC (GSCE).